•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.MiMedx (MDXG) is on the Move, Here's Why the Trend Could be Sustainable
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12%
MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why
MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript
MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
MIMEDX Announces Third Quarter 2024 Operating and Financial Results
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"
THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT
MiMedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript
MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
MIMEDX Announces Second Quarter 2024 Operating and Financial Results
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.